TGTX compared with VCEL: revenue, margins and what each company keeps, and the suppliers and customers both name

TGTXTG Therapeutics, Inc.

Mkt capRevenueRevenue

VCELVericel Corp

Mkt capRevenueRevenue

Compare

TGTXTG Therapeutics, Inc.

VCELVericel Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TGTX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.4%▼−11.26%×0.99

May 6 '26±8.7%▲+16.26%×1.87

Q1 FY26±9.3%▲+4.18%×0.45

Q3 FY25±14.9%▼−3.13%×0.21

VCEL

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.2%▲+2.12%×0.16

May 7 '26±9.1%▼−4.49%×0.49

= impliedTGTX realized, solidVCEL realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

Q1 FY26

±14.8%

▲+1.59%

×0.11

Jan 13 '26±12.9%▲+1.26%×0.10

TGTXTG Therapeutics, Inc.

61.18▼−0.01%· post 59.97· delayed

Mkt cap$9.4BRevenue$240MQ2 FY26Revenue$616MFY25

VCELVericel Corp

40.49▲+0.58%· post 40.49· delayed

After hoursNov 2 '26delayed

Mkt cap$2.1BRevenue$77MQ2 FY26Revenue$276MFY25

Compare

After hoursNov 2 '26delayed

TGTXTG Therapeutics, Inc.

VCELVericel Corp

61.18▼−0.01%post 59.97delayed

Price

40.49▲+0.58%post 40.49delayed

$9.4B

Mkt cap

$2.1B

Q2 FY26$240M

Revenue

$77MQ2 FY26

FY25$616M

Revenue

$276MFY25

TGTX61.18▼−0.01%vsVCEL40.49▲+0.58%After hoursNov 2 '26delayed